On a mission to help create a world where all cancer patients can be cured
Joined May 2024
- Tweets 54
- Following 5
- Followers 66
- Likes 14
33 Photos and videos
Jun 11
Our Co-Founder & CPO will join the Frontiers in Cancer Immunotherapy conference, presenting on how synthetic antigen strategies may enable universal immunotherapies across solid tumors.
Looking forward to engaging with the IO community. Register here: events.nyas.org/cancerio26
20
Jun 5
Last night, we celebrated our Co-Founder & CPO Lex Johnson, PhD at the @PHLBizJournal's 40 Under 40 ceremony. So proud to see Lex honored alongside such an incredible group of leaders.
Congratulations to all of this year's honorees!
1
39
May 21
#ICYMI: Co-founder & CPO Lex Johnson joined @bradloncar on @BiotechTV, covering our first-in-class Flare platform, plus new #ASGCT2026 data on SEND, our novel T cell armoring strategy.
Watch below. biotechtv.com/post/asgct-202…
3
79
May 7
Our name, explained.
“Dispatch” reflects our dual approach: a tumor-specific virus delivers a Flare antigen, which then acts as a beacon to target therapeutics to find & clear #cancer cells, advancing a universal approach across solid tumors.
2
38
Apr 29
Proud to see our co-founder Carl June and founding chairman Jeff Marrazzo recognized as Disruptors of the Year by @ThePhilaCitizen, in honor of their contributions to founding Dispatch & work to translate breakthrough science into real impact for patients. thephiladelphiacitizen.org/r…
1
40
Apr 27
At #ASGCT2026, we’ll present new preclinical data on SEND, a novel synthetic cytokine receptor with the potential to optimize safety and efficacy profiles of immunotherapy treatments. Learn more here: dispatchbio.com/news/dispatc…
3
149
Apr 14
Proud to be part of the @parkerici network and share in their mission to advance scientific discovery into therapeutic progress. Here’s to continuing to work together to improve outcomes for people with cancer.
Read more below.
Thank you to @steveusdin1 and @BioCentury for covering PICI’s mission to close a key biotech gap by translating discovery into real therapies. BioCentury highlights Azalea Therapeutics, @AkamisBio, and PICI portfolio company, @DispatchBio, as powerful examples of PICI’s model in action. Read more here: biocentury.com/article/65907…
1
2
202
Apr 7
Thrilled to share that our co-founder & Chief Platform Officer has been featured in this year’s @PHLBizJournal's 40 Under 40.
This award reflects Lex’s leadership in advancing our mission and contributing to Philadelphia’s growing life sciences community.
2
3
91
Apr 7
Congratulations to all of this year’s honorees. View more info here: bizjournals.com/philadelphia…
26
Mar 24
We’re pleased to share that Chris Wiwi has been promoted to CTO at Dispatch.
An early member of our team, Chris has built and led our technical operations organization spanning CMC development and manufacturing. He will continue to do so as we enter the clinic. Congrats, Chris!
52
Mar 19
Dispatch will participate in the 2026 @sitcancer Spring Scientific in Tucson, in which our CSO, Barbra Sasu, PhD, will present on how synthetic antigen strategies may enable universal immunotherapies across solid tumors.
Looking forward to engaging with the IO community!
1
4
4
1,057
Mar 19
Register to hear about our presentation, among others, at sitcancer.org/edu/2026-sprin…
2
3
352
Mar 13
We were honored to receive the Emerging Company of the Year Award at the @LifeSciencesPA 2026 Annual Dinner & Showcase.
This recognition reflects our team’s persistence and determination to advance new approaches designed to overcome the challenges of treating solid tumors.
1
1
912
Mar 6
This week, Dispatch leadership & co-founders shared our story with the MBC BioLabs community in SF to discuss how we’re advancing a first-in-class platform to overcome targeting and resistance challenges in treating solid tumors. Thanks for hosting!
78
Dispatch Bio retweeted
Congrats to PICI Center Director Carl June, MD, named a Citizen of the Year by @PhilaCitizen. From CAR-T breakthroughs to co-launching @DispatchBio, a PICI portfolio company, Carl is pushing cancer innovation toward a future of universal cancer therapies.
Congrats to Carl June, MD, named a Citizen of the Year (Disruptor of the Year) by @PhilaCitizen. From pioneering CAR-T therapy to launching @DispatchBio—rooted in Philly’s "Cellicon Valley"—his research continues to push the boundaries of cancer treatment. thephiladelphiacitizen.org/m…
1
6
1,187
Feb 17
At #AACRIO26, our co-founder & CPO will highlight our clinical-stage Flare platform.
Flare uses a tumor-specific virus to paint a universal synthetic antigen on tumor cells–enabling precise T cell recognition while reshaping the tumor microenvironment to support immune activity.
1
127
Feb 12
The ECI Advancing Manufacture of Cell & Gene Therapies meeting reinforced the importance of product understanding & analytical rigor in scaling complex therapies–principles that align with how we aim to advance science & engineer a universal treatment across solid tumors.
66
Dispatch Bio retweeted
Congrats to Carl June, MD, named a Citizen of the Year (Disruptor of the Year) by @PhilaCitizen. From pioneering CAR-T therapy to launching @DispatchBio—rooted in Philly’s "Cellicon Valley"—his research continues to push the boundaries of cancer treatment. thephiladelphiacitizen.org/m…
1
6
1,356
Feb 9
In a recent interview, our CSO, Barbra Sasu, shared insights on Dispatch’s novel approach to overcoming longstanding challenges in solid tumors, as well as insights from her extensive experience in drug discovery. Read the full interview here: theconferenceforum.org/edito…
1
50
Feb 9
We look forward to continuing this dialogue at the upcoming #IO360Summit, where Barbra will participate in discussions focused on advancing next-generation immuno-oncology strategies and translating scientific progress into clinical impact. Register here: reg.theconferenceforum.org/e…
56